Bayer AG ((BAYRY)), Bayer Ag (UK) ((GB:0P6S)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Bayer AG is conducting a post-marketing surveillance study titled Post Marketing Surveillance Study for Jivi (Damoctocog Alfa Pegol) in Korean Patients With Hemophilia A. The study aims to assess the safety of damoctocog alfa pegol, a treatment for hemophilia A, in a real-world setting among Korean patients. This research is significant as it provides insights into the treatment’s safety profile beyond controlled clinical trials.
Intervention/Treatment: The study involves the drug damoctocog alfa pegol, known commercially as Jivi. This treatment is designed to replace the missing clotting factor VIII in patients with hemophilia A, helping to prevent or manage bleeding episodes.
Study Design: This is an observational cohort study with a prospective time perspective. Participants will continue their regular medical visits, with data collected over a 36-week period. The study does not involve any additional interventions or masking, as it focuses on real-world data collection.
Study Timeline: The study began on January 24, 2024, with data collection expected to continue until March 2026. The primary completion date is set for 2026, with the last update submitted on July 29, 2025. These dates are crucial for tracking the study’s progress and ensuring timely analysis of the data collected.
Market Implications: This study could impact Bayer AG’s stock performance by providing valuable safety data that may enhance investor confidence in Jivi’s market potential. Positive safety outcomes could strengthen Bayer’s competitive position in the hemophilia treatment market, potentially influencing investor sentiment favorably.
The study is ongoing, with further details available on the ClinicalTrials portal.